Telmisartan alleviates inflammatory response and myocardial apoptosis in diabetic cardiomyopathy rats through TGF-β1/Smad signaling pathway

Minerva Med. 2021 Jun;112(3):411-412. doi: 10.23736/S0026-4806.19.06201-3. Epub 2019 Jul 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Animals
  • Apoptosis / drug effects*
  • Chemokine CCL2 / blood
  • Collagen Type I / metabolism
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Cardiomyopathies / blood
  • Diabetic Cardiomyopathies / drug therapy*
  • Interleukin-2 / blood
  • Lymphotoxin-alpha / metabolism
  • Myocardium / pathology*
  • Random Allocation
  • Rats
  • Smad Proteins / metabolism*
  • Smad3 Protein / blood
  • Telmisartan / pharmacology*
  • Transforming Growth Factor beta1 / metabolism*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Ccl2 protein, rat
  • Chemokine CCL2
  • Collagen Type I
  • Interleukin-2
  • Lymphotoxin-alpha
  • Smad Proteins
  • Smad3 Protein
  • Smad3 protein, rat
  • Tgfb1 protein, rat
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • Telmisartan